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Abstract: Stroke is a rare but possible complication after atrial fibrillation (AF) ablation. However, its
etiopathogenesis is far from being completely characterized. Here we report a case of stroke, with
recurrent peripheral embolism after AF ablation procedure. In our patient, an in situ femoral vein
thrombosis and iatrogenic atrial septal defect were simultaneously detected. A comprehensive review
of multiple pathophysiological mechanisms of stroke in this context is provided. The case underlines
the importance of a global evaluation of patients undergoing AF ablation.
Keywords: atrial fibrillation ablation; stroke; iatrogenic interatrial septum defect; paradoxical
embolism; anticoagulant interruption
1. Case Report
A gentleman, 76 years old, was scheduled for catheter ablation of atrial fibrillation (AF) and
atypical left atrial flutter in the context of symptomatic left ventricular dysfunction. He reported
fatigue and exertional dyspnea, and presented persistent AF on EKG. He had a weight of 68 kg, and a
height of 170 cm (BMI = 23 kg/m2), with high estimated thromboembolic risk (CHA2DS2VASc = 4).
He was previously prescribed with anticoagulation (Dabigatran 110 mg bid), beta-blocker (bisoprolol
5 mg od), ACE-inhibitor (ramipril 5 mg od), diuretic (furosemide 50 mg) therapy. A 2D-echocardiogram
documented left ventricle dilation (LVEDD (end diastolic diameter): 61 mm) with systolic dysfunction
(EF (ejection fraction): 38%). A 2D-transesophageal echocardiogram (TEE) showed absence of images
referable to atrial and auricular thrombosis. Single-lobe left appendage displayed reduced function
with velocity peaks of 25 cm/sec. The left atrial area was 28 cm2. No relevant atherosclerotic plaques
were found in the thoracic aorta. Written informed consent was obtained and the patient underwent
radiofrequency electrical pulmonary veins isolation plus roof and mitral isthmus ablation lines
during systemic intraprocedural heparinization (activation clotting time (ACT)-target: 300–350 s).
Electrical cardioversion was also performed due to presence of persistent AF. The total procedural
time was 180 min. Dabigatran was temporarily interrupted for 36 h across the procedure and the
patient was discharged the next day. After one week he was admitted to the emergency department
for sudden dyspnea, being hospitalized for acute heart failure. At admission the EKG showed
sinus tachycardia, while chest X-ray depicted bilateral alveolar edema. During hospitalization, after
achieving hemodynamic stabilization, the patient suffered aphasia and space-time disorientation
with near loss of consciousness. The Angio-CT (computational tomography) showed hypodense
lesions in the left cortico-subcortical temporo-occipital area and in the left cerebellar hemisphere
as showed in Figure 1. Carotid and vertebral arteries were free from hemodynamic atherosclerotic
plaques. Symptoms completely disappeared after two days and at the 24 h CT scan control, the lesions
were stable, in the absence of hemorrhagic transformation. After a few days, the patient complained
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left limb pain and an acute distal embolism was diagnosed. A new transthoracic echocardiogram
revealed a further deterioration of left ventricular ejection fraction (EF: 30%) with no evidence of
intraventricular thrombosis and a clearly discernable interatrial septal defect with left-to-right shunt,
this was likely attributable to the trans-septal puncture performed during the ablation (Figure 2).
Ultrasonography of the groin region documented in situ not compressible left femoral vein thrombosis
(Figure 3). Non fractioned heparin infusion was administered with complete resolution of both the
arterial embolic occlusion and venous thrombosis. After a few days, oral anticoagulation with apixaban
was initiated and the patient was discharged. At the six months follow-up, he presented with mild
cognitive impairment, which persisted overtime till the last visit.
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2. Case Discussion
The case illustrates an uncommon complication after atrial fibrillation (AF) ablation manifested
with recurrent embolic events: A stroke and a leg embolism. Although stroke is a well-known described
complication after AF ablation, the etiopathogenetic mechanisms underlying this complication are yet
to be completely characterized. Here, we summarize and discuss all the potential factors involved in
this undesirable complication.
2.1. Radiofrequency Lesion Set and Ablation “Per Se”
Evidence from non-randomized studies has shown that AF catheter ablation may reduce stroke
risk, when successful. Among 361,913 patients with AF of the Swedish Patient Registry, catheter
ablation was associated with a lower risk of stroke (HR = 0.69) and mortality (HR = 0.50). These results
were even more significant in patients with CHA2DS2-VASc score ≥2 (HR = 0.39) [1]. Especially in
patients with CHA2DS2-VASc score of≥2 (83% of 3953 patients) Saliba and colleagues found a reduction
in stroke rate in the ablation group compared to the non-ablated group (HR = 0.61) [2]. On this ground,
Hunter et al. demonstrated, in an international multicenter registry of 1273 patients, that freedom
from AF was associated with stroke-free survival (HR = 0.30) [3]. However, when discussing the
possibility of a catheter ablation procedure for AF treatment, physicians should clearly make their
patients aware about a periprocedural stroke risk which is approximately 0.5–1% [4]. Thromboembolic
risk is directly related to the amount of radiofrequency lesions applied in the left atrial cavity. In fact,
radiofrequency produces colliquative necrosis, thus leading to endothelial dysfunction and activation
of the Virchow triad. Hence, during ablation, tissue involvement is directly related to an increased
embolic risk [5]. An approach adding linear or complex lesion sets to pulmonary vein isolation (PVI)
did not demonstrate an increase in freedom from AF recurrences, thus the standard endpoint during the
first procedure should be PVI alone [6]. In our case, extensive left atrial ablation was performed with
PVI plus tracing of two ablation lines along the roof and the mitral isthmus. Such ablation strategy was
due to the presence of atypical left atrial flutter as well as of persistent atrial fibrillation. Although stroke
is considered an uncommon complication after AF ablation, a growing body of evidence is consistently
reporting asymptomatic or subclinical ischemic lesions in up to 41% of patients [7,8]. An elegant
Italian study by Gaita and colleagues analyzed postprocedural brain magnetic resonance imaging
(MRI) of 232 consecutive patients with paroxysmal or persistent atrial fibrillation who underwent
radiofrequency left atrial catheter ablation. Techniques used were PVI or PVI plus linear lesions plus
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atrial defragmentation. A clinical cerebrovascular accident occurred in only 1 patient. However,
brain MRI returned positive for new embolic lesions in 33 patients. Cardioversion (CV) during the
procedure was associated with an increased risk of 2.75 (95 confidence interval, 1.29–5.89; p = 0.009) [9].
Our patient underwent electrical CV during the ablation due to the presence of persistent AF at the
beginning of the procedure. It has been recognized that CV is related to thromboembolic events “per se”,
independently by the ablation procedure. In patients undergoing TEE-guided cardioversion, patients
on direct oral anticoagulants (DOACs), such as dabigatran and apixaban, experienced low incidence of
thromboembolic events during follow-ups (0.6% and 1.1%, respectively), similar to warfarin, with a
favorable trend of bleeding safety profile [10,11]. The highest risk period after CV is the following week,
which would be a suitable timeline for our patient considering the stroke and the peripheral embolism.
Finally, it seems that techniques other than radiofrequency, such as cryoballoon based one-shot
ablation and duty-cycled phased radiofrequency ablation (PVAC) are not free from silent cerebral
embolisms, suggesting other mechanisms (like air embolism) could play a pivotal role in the
physiopathology of these subclinical findings [12–14].
2.2. Management of Anticoagulant Therapy in the Periprocedural Period
Ablation was performed in January 2017. The patient had been prescribed Dabigatran 6 months
before. We decided to perform TEE due to the patient’s high thromboembolic risk (CHA2DS2VASc = 4).
Indeed, despite optimal oral anticoagulation with DOACs, left atrial (LA) thrombus was detected
in the left appendage (LAA) in >3.6% of AF patients undergoing catheter ablation in the real world.
In this setting higher CHA2DS2VASc (p = 0.02), but not the type of DOAC, significantly predicted the
presence of LA thrombus [15].
Dabigatran has been available in Italy since 2014. At the time of ablation there were no
clear guidelines on appropriate periprocedural ablation management of such a new kind of drug.
On the contrary, evidence available on uninterrupted warfarin showed reduction in bleeding and
thromboembolic complications [16]. Since we used all the available tools in order to reduce bleeding
complications (i.e., ultrasound guided femoral veins puncture, intracardiac echocardiography, contact
force sensing catheters) [17,18], we felt confident to minimize dabigatran interruption. In fact, the last
assumption was in the morning of the day before, and first retake was in the evening of the day of the
procedure (36 h, total interruption time). Despite this short interruption and the use of heparinization
during the procedure (target activation clotting time ACT = 300–350 s), we should consider this
anticoagulation break as a putative factor implicated in the patient’s recurrent embolic events. Indeed,
the 2017 expert consensus statement on AF Ablation provide a Class I recommendation for performing
the procedure with uninterrupted dabigatran (Class I, LOE A) or rivaroxaban (Class I, LOE B-R),
and a 2A recommendation for the other Xa inhibitors for which specific clinical studies had not been
performed at the time [5]. These recommendations derived from the results of the RE-CIRCUIT trial
which was a head-to-head comparison between uninterrupted dabigatran and uninterrupted warfarin
in patients undergoing AF ablation. The incidence of major bleeding was significantly lower with
dabigatran than with warfarin (5 patients (1.6%) vs 22 patients (6.9%)). No strokes/TIA (transient
ischemic attack) occurred in the dabigatran arm, while there was one TIA in the warfarin group.
Idarucizumab, the specific reversal agent, was never used during the study [19]. Two years before,
Cappato and colleagues published the results of the VENTURE-AF trial, comparing uninterrupted
rivaroxaban vs uninterrupted warfarin. Complications (a major bleeding event, one ischemic stroke,
and one vascular death) occurred only in the warfarin group [20]. More recently consistent evidences
were provided also for apixaban and edoxaban. The AEIOU trial, published in 2018, randomized
300 patients undergoing AF ablation to uninterrupted versus minimally interrupted (holding 1 dose)
periprocedural apixaban. A retrospective cohort of patients treated with uninterrupted warfarin at
the same centers was matched to the apixaban-treated subjects for comparison. There were no stroke
or SE events observed in all groups. The rates of clinically significant, major bleeding were similar
for all apixaban patients compared with the matched warfarin group [21]. Finally, in 2019 Hohnloser
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et al. published results from the ELIMINATE-AF trial, which confirmed the safety and efficacy of
uninterrupted edoxaban vs vitamin K antagonists (VKAs) in the same setting. Among 553 patients
undergoing AF ablation, brain magnetic resonance imaging was performed in 177 subjects to assess
silent cerebral infarcts. There was one ischaemic and one haemorrhagic stroke, both in patients on
edoxaban. Cerebral microemboli were detected in 13.8% (16) of patients who received edoxaban
and 9.6% (5) of patients in the VKA group (p= ns) [22]. Based on these clinical trials, it is now clear
that a strategy of performing AF ablation on patients receiving uninterrupted anticoagulation can
be performed safely and will minimize the risk of thromboembolic events. Finally, international
guidelines state in the absence of controlled trial data, anticoagulation management after AF ablation
should follow general recommendations (i.e., on the basis of CHA2DS2-VASc score), regardless of the
presumed rhythm outcome [23].
2.3. Iatrogenic Interatrial Septal Defect, In Situ Thrombosis and Paradoxical Embolism
The diagnosis in our patient, of simultaneous iatrogenic interatrial septal defect (IASD) and
in-situ thrombosis, is rather unique. These are two well characterized phenomena that have rarely
been discovered together in this setting. Real incidence of IASD after AF ablation is under debate.
Older studies, using transesophageal echocardiography (TEE), reported up to 19% rate during
follow-up [24–27].
More recently, other rates have been described (5.6% following a first procedure and 2.2% following
a second procedure) [28].
The risk of persistent IASD is in part related to the tools, technologies, and approaches used
for catheter ablation. For example, the incidence of IASD at 1-year follow-up following cryoballoon
ablation procedure for PVI is significantly higher in front of radiofrequency procedures [29–31]. After a
single-puncture, using the robotic navigation system, an IASD was detected in 38 of 40 (95%) patients
one day after the ablation. At 6-months follow up, the IASDs were closed only in 30 of 39 (78.9%)
patients. The authors also addressed that persistent IASDs are not associated with an increased rate of
paradoxical embolism or with relevant shunting [32].
On the other side, the real incidence of in situ asymptomatic femoral thrombosis after AF ablation
is unknown. Asymptomatic deep venous thrombosis (DVT) formation, following sheath placement for
electrophysiological studies (EPS) in general, were detected in up to 16–44% of patients. In contrast,
symptomatic DVTs are much lower (0.5–0.8%) [33]. In 2004, Chen and colleagues reported a significant
incidence (17.6%) of non-occlusive DVT after multiple sheath placements for EPS. Nonetheless, in
the study, all venous thrombi were non-occlusive and asymptomatic. None of the femoral veins
developed occlusive DVT [34]. Although there are weak supporting data, it is reasonable to conclude
that limiting the number and the size of femoral vein sheaths on the same side can minimize thrombosis
risk. Despite the fact that there are no large prospective or randomized trials, prophylactic heparin
administration during the procedure may be considered on an individual basis for right chamber
ablations, particularly for longer procedures, or in high-risk patients [35]. Large emboli migrated from
leg veins can lodge in the right ventricle [36], whereas smaller emboli are likely to pass unimpeded to the
pulmonary arteries. The occurrence of pulmonary embolism following EP procedures has previously
been reported, especially in patients with a thrombophilic state [37]. Moreover, two cases of floating
atrial thrombi following EP studies were successfully treated with thrombolysis in asymptomatic
patients [38].
To the best of our knowledge, there are no reported cases of paradoxical embolism following
AF ablation where in situ thrombosis and iatrogenic atrial septal defect are detected simultaneously.
Indeed, DVT developed despite fully systemic heparinization during the procedure and minimal oral
anticoagulation interruption.
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3. Conclusions
In conclusion, we report a case of stroke and peripheral embolism after atrial fibrillation ablation
procedure. In our patient an in situ femoral vein thrombosis and iatrogenic atrial septal defect were
simultaneously detected. We highlighted and discussed each etiopathogenetic mechanism underlying
this clinical condition. The case encourages a critical clinical and instrumental evaluation in the
management of such undesirable complications.
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